Cancer meets obesity - Metabolic dysfunction (obesity. diabetes, etc.) makes cancer more aggressive. SynDevRx is pioneering the metabo-oncology field with a first-in-class therapeutic targeting cancer patients with metabolic dysfunction. This overlooked patient population is estimated at >700,000/year in the US. We are in multiple Phase 2 clinical studies in breast cancer and prostate cancer with a unique value proposition. Our lead asset 'evexomostat' has dual action - anti-angiogenic/anti-tumor plus a potent and clinically validated metabolic correction activity.
Looking for a particular SynDevRx, Inc. employee's phone or email?
The SynDevRx, Inc. annual revenue was $6 million in 2026.
James Shanahan is the Co-Founder, Chief Business Officer of SynDevRx, Inc..
6 people are employed at SynDevRx, Inc..
SynDevRx, Inc. is based in Cambridge, Massachusetts.
The NAICS codes for SynDevRx, Inc. are [32, 325, 3254, 32541].
The SIC codes for SynDevRx, Inc. are [283, 28].